Exhibit 99.1
TITLE OF CRADA: Development of NCI Proprietary Adoptive T Cell Therapies Using Autologous Peripheral Blood Cells with Naturally Occurring Endogenous Anti-Tumor Activity that are Genetically Modified Using Retroviral Vectors Encoding Intrexon Proprietary Controlled IL-12, for Use in the Immunotherapy of Patients with Metastatic Cancer
| PHS NCI Component: | National Cancer Institute (NCI) | |
| IC Principal Investigator: | Steven A. Rosenberg, M.D., Ph.D. | |
| Collaborator: | Intrexon Corporation | |
| Collaborator Principal Investigator: | Gregory I. Frost, Ph.D. | |
| TERM OF CRADA: | Five (5) years from the Effective Date. | |
ABSTRACT OF THE RESEARCH PLAN:
The principal goal of this CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes (PBL) with naturally occurring endogenous anti-tumor activity combined with the proprietary Intrexon Corporation (“Intrexon”) molecular RheoSwitch Therapeutic System (RTS®) for introducing spatially and temporally controlled Interleukin-12 (IL-12) expression in ACT/PBL/IL-12 for the treatment of patients with solid tumor malignancies.
5